Nuveen’s Protara Therapeutics TARA Stock Holding History

Nuveen’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$333K	Sell	63,860 -22,641	-26%	-$134K	﹤0.01%	2984
2025 Q4	$461K	Sell	86,501 -196,980	-69%	-$1.1M	﹤0.01%	2909
2025 Q3	$1.23M	Buy	283,481 +181,880	+179%	+$589K	﹤0.01%	2524
2025 Q2	$308K	Buy	+101,601	New	+$350K	﹤0.01%	3041
2021 Q2	–	Sell	-13,940	Closed	-$219K	–	3527
2021 Q1	$219K	Sell	13,940 -10,707	-43%	-$199K	﹤0.01%	3215
2020 Q4	$597K	Buy	+24,647	New	+$531K	﹤0.01%	2994

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Nuveen's TARA Position: Q1 2026 in Review

Nuveen reduced its Protara Therapeutics (TARA) stake by 26% in Q1 2026, selling an estimated $134K and leaving 63,860 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #2984.

Nuveen first reported a position in TARA in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.23M in Q3 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

Nuveen held 63,860 shares of Protara Therapeutics worth $333K as of Q1 2026.
Nuveen sold 22,641 Protara Therapeutics shares in Q1 2026, an estimated $134K.
Protara Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2984 holding.
Nuveen first reported a position in Protara Therapeutics in Q4 2020 and has held it in 6 quarters since.
Nuveen's Protara Therapeutics position peaked at $1.23M in Q3 2025.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.